Nuvectis Pharma, Inc. (NVCT) intrinsic value & 10-year financials
Nuvectis Pharma, Inc. (NVCT) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $18.60
- Market cap
- $405.7M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -296.9%
- Free cash flow (FY2025)
- —
NVCT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$26.4M | -$1.32 | — | — | -188.0% |
| FY2024 | — | -$19.0M | -$1.11 | — | — | -173.4% |
| FY2023 | — | -$22.3M | -$1.43 | — | — | -168.5% |
| FY2022 | — | -$19.1M | -$1.51 | — | — | -1188.7% |
| FY2021 | — | -$12.9M | -$1.01 | — | — | 234.0% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Nuvectis Pharma, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Nuvectis Pharma, Inc. has historically struggled to out-earn its cost of capital, averaging just -3.0% ROIC.
Nuvectis Pharma, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Nuvectis Pharma, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.